Products
Setrusumab Biosimilar Monoclonal Antibody (SOST) for Research
Pre-Made Setrusumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Setrusumab is a fully human anti-sclerostin IgG2 monoclonal antibody, being developed by Mereo Biopharma, for the treatment of osteogenesis imperfecta.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-517-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Setrusumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody |
| INN Name | Setrusumab |
| Target | SOST |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | MorphoSys;Novartis;Mereo BioPharma |
| Conditions Approved | na |
| Conditions Active | Osteogenesis imperfecta |
| Conditions Discontinued | Hypophosphatasia;Postmenopausal osteoporosis |
| Development Tech | MorphoSys HuCAL Phage Display |
About target - SOST
1. Protein Sclerostin
2. Gene SOST
3. Organism Homo sapiens (Human)
Function
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
